On October 29, 2025 NovaBridge Biosciences (NovaBridge or the Company) reported that it has changed its corporate name from I-Mab to NovaBridge Biosciences. The change was overwhelmingly approved by shareholders at the Company’s Extraordinary General Meeting held on October 24, 2025, and by the Company’s Board of Directors. The Company’s American Depositary Shares (ADSs) will trade on Nasdaq under the new name and a new ticker symbol, "NBP", effective at the opening of trading on October 30, 2025, replacing its current symbol "IMAB" (Nasdaq: IMAB).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new corporate brand, including a new website (www.novabridge.com), marks an important step in the Company’s strategic transformation to a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide.

In connection with the name change and ticker symbol change, no action is required from current shareholders and the Company’s CUSIP number will remain the same. Historical trading data of the Company’s ADSs prior to October 30, 2025 may not yet be available on certain third-party websites and apps when searching for "NovaBridge Biosciences" and/or "NBP", in which case such data may temporarily be found under "I-MAB" and/or "IMAB".

"Our new corporate branding successfully conveys the key elements of our new strategy, bridging collaboration, translational science, and execution to rapidly progress transformative therapies and strategically create significant value for patients and investors," said Mr. Fu Wei, Executive Chairman of NovaBridge. "Our proposed dual listing on both Nasdaq and HKEX, a key element of our global growth strategy, will enable us to broaden and diversify our investor base, and enhance trading liquidity and access to capital, while strengthening our presence with key stakeholders in the rapidly growing Asian market."

"NovaBridge’s new brand identity successfully aligns with our strategic transition to a global biotech platform. The recent presentation of encouraging updated Phase 1 monotherapy data at the Triple Meeting1 for givastomig, a potential best-in-class Claudin 18.2-directed therapy for gastric cancers, and the formation of our new subsidiary, Visara, and its recent acquisition of VIS-101, a second-in-class potentially best-in-class bifunctional VEGF-A/ANG2 targeted biologic, provide positive validation of our new strategy. We continue to progress givastomig towards a global randomized Phase 2 study, expected to achieve enrollment of the first patient in Q1 2026," said Sean Fu, PhD, Chief Executive Officer of NovaBridge. "We are pleased by the positive momentum from our new strategy, accented by our new corporate brand, and are optimistic that our global biotech platform will enable us to realize the full potential of innovative medicines and create value for patients and investors."

The NovaBridge Business Model and Pipeline

The Company intends to partner with leading innovators to identify and accelerate high-value assets. Our model integrates rigorous asset selection, bespoke translational strategies, and efficient clinical execution. With the backing of CBC Group, we leverage deep local insights and global capabilities to develop the most promising drug candidates across a range of therapeutic categories.

The Company will utilize a "hub-and-spoke" model to create and advance specialized subsidiary companies (spokes) which maintain operational focus and agility. By focusing each spoke on a specific asset or therapeutic area, the Company can optimally manage risk and create value through potential partnering transactions.

Pipeline:

Givastomig, a potential best-in-class Claudin 18.2 X 4-1BB bispecific antibody, is in Phase 1b clinical trials for the potential treatment of gastric cancer and other Claudin 18.2-positive gastrointestinal malignancies. A global, randomized Phase 2 study is planned, with the enrollment of the first patient targeted in Q1 2026. Givastomig is being jointly developed through a global partnership with ABL Bio, in which NovaBridge is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.

Ragistomig is an anti-PD-L1 X 4-1BB bispecific antibody. Built on Phase 1 clinical data, an ongoing Phase 1b study designed to expand the therapeutic index is expected to yield results in 2H 2026. The program is being jointly developed with ABL Bio.

Uliledlimab targets CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. Progression free survival (PFS) data are expected in 2H 2026 from an ongoing randomized Phase 2 trial evaluating uliledlimab + toripalimab compared to pembrolizumab alone or toripalimab alone in a CD73 selected population. NovaBridge owns worldwide rights to uliledlimab outside of Greater China.

VIS-101, acquired by Visara, a newly formed NovaBridge subsidiary, under the new business model, is a bifunctional biologic targeting VEGF-A and ANG2, currently in Phase 2 development

VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, and a more potent molecule that could potentially provide more durable treatment benefits for patients with wet AMD, DME, and retinal vein occlusion (RVO) than current standard of care. VIS-101 has completed initial safety and dose-escalation studies in both the US and China, and is currently completing a randomized, dose-ranging Phase 2 study in China. VIS-101 is anticipated to be Phase 3-ready in 2026.

Acquisition completed by a newly formed subsidiary, Visara. Visara, a clinical-stage biopharmaceutical company focusing on the development of best-in-class ophthalmic therapeutics, was launched with an approximately $37M capital infusion from NovaBridge and the contribution of certain rights by a strategic partner. NovaBridge is the majority shareholder of Visara, and Visara controls global rights to VIS-101.

Visara is led by Co-Founder and Executive Chairman Emmett T. Cunningham, Jr., MD, PhD, MPH. Dr. Cunningham has been a physician, innovator, entrepreneur, and investor for more than 25 years, formerly serving as Senior Managing Director at Blackstone Group L.P. and Managing Director at Clarus Ventures, LLC. Dr. Cunningham is also an internationally recognized specialist in infectious and inflammatory eye disease with over 450 co-authored publications.

1. The AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) is also known as the Triple Meeting, held in Boston, Massachusetts October 22-26, 2025

(Press release, I-Mab Biopharma, OCT 29, 2025, View Source [SID1234660986])